Endo, Inc.
Endo, Inc. operates as a specialty pharmaceutical company that develops, manufactures, markets, and sells various pharmaceutical products and provides life-enhancing therapies in the United States and internationally. It offers specialty medicines, sterile injectables, and generic products. The company offers products for the treatment of conditions in urology, orthopedics, and endocrinology. It … Read more
Market Cap & Net Worth: Endo, Inc. (NDOI)
Endo, Inc. (OTCQX:NDOI) has a market capitalization of $1.93 Billion ($1.93 Billion) as of March 18, 2026. Listed on the OTCQX stock exchange, this USA-based company holds position #7233 globally and #3883 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Endo, Inc.'s stock price $25.30 by its total outstanding shares 76313504 (76.31 Million).
Endo, Inc. Market Cap History: 2024 to 2025
Endo, Inc.'s market capitalization history from 2024 to 2025. Data shows growth from $1.74 Billion to $1.93 Billion (0.00% CAGR).
Endo, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Endo, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NDOI by Market Capitalization
Companies near Endo, Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to Endo, Inc. by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Endo, Inc. Historical Marketcap From 2024 to 2025
Between 2024 and today, Endo, Inc.'s market cap moved from $1.74 Billion to $ 1.93 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $1.93 Billion | +10.96% |
| 2024 | $1.74 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Endo, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.93 Billion USD |
| MoneyControl | $1.93 Billion USD |
| MarketWatch | $1.93 Billion USD |
| marketcap.company | $1.93 Billion USD |
| Reuters | $1.93 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.